Medtronic plans to study the device in patients with peripheral artery disease below the knee, a historically difficult condition to treat.
Medtronic drug-coated balloon gets FDA breakthrough status Read More »
The innovation challenge is focused on developing home devices that could help reduce hospital readmissions.
FDA selects first 5 participants for READI-Home initiative Read More »
The regulatory authorizations come as Medtronic looks to differentiate itself in the fast-growing pulsed field ablation market targeted by rivals Abbott, Boston Scientific and J&J.
Medtronic reveals cardiac mapping and ablation software clearances Read More »
Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could help carve out a place in a crowded market that already includes AbbVie’s Humira and UCB’s Bimzelx.
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease Read More »
Although artificial intelligence has quickly become integrated into our daily lives, Americans say they’re becoming increasingly concerned about their health data, making them less likely to use it for tasks like finding providers, according to a new survey.
Data privacy concerns could hold patients back from using AI Read More »
Amid rising industry concerns about U.S. competitiveness with China, the Trump administration is rolling out four ARPA-H initiatives to modernize clinical trial design, site activation, consent and patient data collection.
US government launches AI-driven programs to overhaul clinical trials Read More »
Despite meeting the primary endpoints in a Phase 3 trial, shares of Zealand Pharma dropped in premarket trading Thursday as the up to 9.8% weight loss reflected inferior loss to that generated by competitors.
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again Read More »
Patients had adverse events after receiving a Fresenius Kabi medicine that experienced manufacturing deviations.
Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse events Read More »
Foghorn Therapeutics and Eli Lilly teamed up in 2021 to develop and commercialize oncology products. The biotech’s layoffs will leave the company with 65 employees as it refocuses on its proprietary portfolio programs.
Foghorn lays off 40% of staff after Lilly collaboration ends Read More »
Bristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s program have caused some unease about the drug class.
BMS reports liver injury events in lung disease program, with key readout near Read More »
